Regenerativ medicin
Health ministry panel conditionally approves iPS cell products
Rapporterad av AI Bild genererad av AI
A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.
Following an expert panel's recommendation last month, Japan's Health, Labor and Welfare Ministry on March 6 conditionally approved two iPS cell-derived regenerative medicines—the world's first commercialized such treatments—for severe heart failure and Parkinson's disease. The products carry conditions and time limits, with pricing and insurance coverage decisions next; sales could begin as early as summer 2026.
Rapporterad av AI Faktagranskad
Forskare vid Northwestern University säger att de utvecklat en avancerad labodlad modell av humana ryggmärgorganoider som reproducerar nyckelfunktioner hos traumatiska skador – såsom inflammation och gliasärbildning – och att en experimentell ”dansande molekyler”-terapi minskade ärrliknande vävnad och främjade nervtrådstillväxt i modellen.